Anosmia Market Report 2026

The anosmia market size has grown strongly in recent years. It will grow from $3.86 billion in 2025 to $4.23 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased incidence of viral-induced anosmia, growing awareness of olfactory disorders, wider availability of diagnostic tools, expansion of ENT specialty care, increased reporting of sensory loss.

The anosmia market size is expected to see strong growth in the next few years. It will grow to $6.07 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rising research into olfactory nerve regeneration, growing adoption of novel therapies, expansion of post-infectious care programs, increasing demand for quality-of-life treatments, growing clinical trial activity. Major trends in the forecast period include increasing focus on regenerative therapies, rising use of smell training programs, growing adoption of targeted pharmacological treatments, expansion of diagnostic imaging and testing, enhanced emphasis on post-viral recovery management.

The increasing prevalence of neurological disorders is expected to drive the growth of the anosmia market in the coming years. Neurological disorders include a wide range of conditions that impact the nervous system, encompassing the brain, spinal cord, and peripheral nerves throughout the body. The growing occurrence of neurological disorders is attributed to an aging population and the higher prevalence of chronic conditions such as diabetes and hypertension. These disorders can lead to anosmia by damaging the olfactory pathways or brain regions responsible for processing smell, resulting in a reduced or complete loss of the ability to perceive odors. For example, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections suggesting this number could reach 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is contributing to the expansion of the anosmia market.

Major companies operating in the anosmia market are concentrating on developing advanced delivery systems, such as soft-mist nasal sprays, to enhance efficacy, improve drug absorption, and target the olfactory region more accurately. Soft-mist nasal spray technology employs controlled droplet size and low spray velocity to maximize deposition in the olfactory region, thereby increasing therapeutic effectiveness. For example, in April 2025, Cyrano Therapeutics, a U.S.-based clinical-stage regenerative medicine company, completed enrollment in the Phase 2 FLAVOR trial of its soft-mist nasal spray candidate, CYR-064, for post-viral smell loss. The product incorporates a patent-protected intranasal formulation of a broad-spectrum phosphodiesterase (PDE) inhibitor designed to enhance olfactory neuron excitability, and, by utilizing the Ursatec 3K pump system in combination with Resyca’s soft-mist spray technology, it achieves precise and targeted deposition into the olfactory region.

In November 2023, Fifth Sense, a UK-based charity organization, collaborated with ENT UK to enhance care for individuals affected by smell and taste disorders. Through this collaboration, both organizations aim to provide support to patients and healthcare professionals dealing with smell and taste disorders, including anosmia. ENT UK is a UK-based professional membership body representing ear, nose, and throat surgeons.

Major companies operating in the anosmia market are Cyrano Therapeutics, Regeneron Pharmaceuticals, Novartis AG, GlaxoSmithKline PLC, Otsuka Pharmaceutical Co Ltd, Bayer AG, AstraZeneca PLC, Eli Lilly and Company, Pfizer Inc, Sanofi SA, NeuroNascent Inc, Immunome Therapeutics, Olfactory Therapeutics Ltd, ENT Therapeutics Inc, NeuroSense Therapeutics LLC, SmellSense Bio, Olfactricity Therapeutics, Sensory Neurogenics Inc, Olfaxion Biotech, SmellGen Therapeutics, Post‑Viral Sensory Recovery Inc, Hyposmia Therapeutics LLC.

North America was the largest region in the anosmia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the market going forward. The regions covered in the anosmia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anosmia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the anosmia market by increasing costs of imported diagnostic equipment, imaging systems, pharmaceutical compounds, and therapeutic devices used in smell disorder management. ENT clinics and hospitals in North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces pricing pressure on specialty medications. These tariffs raise diagnostic and treatment costs for patients. However, they also encourage local manufacturing of diagnostic tools and regional development of therapeutic solutions.

The anosmia market research report is one of a series of new reports that provides anosmia market statistics, including anosmia industry global market size, regional shares, competitors with a anosmia market share, detailed anosmia market segments, market trends and opportunities, and any further data you may need to thrive in the anosmia industry. This anosmia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anosmia is a medical condition characterized by the complete or partial loss of the sense of smell. It may arise from various factors affecting the olfactory system, such as nasal congestion, nasal polyps, neurological disorders, head injuries, viral infections, or exposure to specific chemicals or medications. Anosmia can be either temporary or permanent and may involve one or both nostrils. It frequently diminishes the ability to perceive or recognize odors, influencing an individual's sense of taste and overall quality of life.

The primary categories in the anosmia market are idiopathic anosmia and congenital anosmia. Idiopathic anosmia refers to the loss of the sense of smell without a known cause, even after comprehensive medical evaluation and diagnostic testing. The available treatments include therapies and medications, with various end users such as hospitals, clinics, and others.

The anosmia market consists of revenues earned by entities by providing services such as olfactory testing and imaging, medical consultations, therapeutic services, medication management, rehabilitative services including psychological support and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The anosmia market also includes sales of diagnostic tools, medical devices, and nasal sprays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.